Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Deciphera Pharmaceuticals (DCPH – Research Report) and Shockwave Medical (SWAV – Research Report).
Deciphera Pharmaceuticals (DCPH)
In a report released today, Reni Benjamin from JMP Securities reiterated a Buy rating on Deciphera Pharmaceuticals, with a price target of $23.00. The company’s shares closed last Friday at $15.34.
According to TipRanks.com, Benjamin is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Currently, the analyst consensus on Deciphera Pharmaceuticals is a Moderate Buy with an average price target of $22.67.
See today’s best-performing stocks on TipRanks >>
Shockwave Medical (SWAV)
In a report issued on April 5, Imron Zafar from Deutsche Bank downgraded Shockwave Medical to Hold, with a price target of $335.00. The company’s shares closed last Friday at $326.34, close to its 52-week high of $331.58.
Zafar has an average return of
According to TipRanks.com, Zafar is ranked #2647 out of 8789 analysts.
Shockwave Medical has an analyst consensus of Hold, with a price target consensus of $298.13, implying a -8.4% downside from current levels. In a report issued on April 4, Wolfe Research also downgraded the stock to Hold.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on DCPH:
